Johnson & Johnson (NYSE:JNJ) Shares Up 1.3% on Analyst Upgrade

Johnson & Johnson logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Johnson & Johnson shares rose 1.3% after JPMorgan raised its price target from $285 to $300, while keeping a neutral rating.
  • Analyst sentiment remains broadly positive: MarketBeat reports a “Moderate Buy” consensus and an average price target of $276.54.
  • J&J’s latest quarterly results modestly beat earnings and revenue estimates, with revenue up 5.9% year over year; the company set 2026 EPS guidance of $11.05–$11.15.
  • MarketBeat previews the top five stocks to own by December 1st.

Johnson & Johnson (NYSE:JNJ - Get Free Report)'s share price shot up 1.3% on Friday after JPMorgan Chase & Co. raised their price target on the stock from $285.00 to $300.00. JPMorgan Chase & Co. currently has a neutral rating on the stock. Johnson & Johnson traded as high as $272.50 and last traded at $270.5380. Approximately 11,915,887 shares changed hands during trading, an increase of 50% from the average session volume of 7,962,709 shares. The stock had previously closed at $267.14.

A number of other brokerages also recently commented on JNJ. Erste Group Bank downgraded Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Wednesday, October 21st. Johnson Rice cut Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Wednesday, October 21st. Evercore set a $300.00 price objective on Johnson & Johnson in a research report on Tuesday, October 20th. Leerink Partners dropped their target price on Johnson & Johnson from $276.00 to $272.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 14th. Finally, UBS Group set a $270.00 target price on Johnson & Johnson in a research note on Wednesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus target price of $276.54.

Check Out Our Latest Analysis on Johnson & Johnson

Insider Activity

In other news, EVP Elizabeth Forminard sold 13,072 shares of the company's stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total value of $3,717,546.08. Following the completion of the sale, the executive vice president directly owned 16,994 shares of the company's stock, valued at approximately $4,832,923.66. This represents a 43.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares of the company's stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.16% of the stock is currently owned by company insiders.

Recent Johnson & Johnson Headlines

Here are a few of the latest headlines about JNJ:

  • Positive Sentiment: The company has asked the FDA to expand CAPLYTA’s use to bipolar I mania or mixed episodes, supported by two positive Phase 3 studies. Approval would provide another potential use for the medicine. CAPLYTA FDA filing
  • Neutral Sentiment: JPMorgan raised its JNJ price target from $285 to $300 but maintained a “neutral” rating, signaling a higher valuation estimate without a more bullish recommendation. JPMorgan target update
  • Negative Sentiment: A Louisiana appellate court upheld a multimillion-dollar talc verdict and increased damages, adding to J&J’s litigation-related financial risk. A law firm also announced an investor-claims investigation, though that announcement alone does not establish wrongdoing. Louisiana talc appeal coverage

Hedge Funds Weigh In On Johnson & Johnson

Several large investors have recently made changes to their positions in the business. Outlook Capital Management LLC bought a new position in Johnson & Johnson during the second quarter valued at approximately $28,000. Matrix Trust Co grew its position in Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after acquiring an additional 54 shares in the last quarter. Navigoe LLC increased its stake in shares of Johnson & Johnson by 60.4% during the 3rd quarter. Navigoe LLC now owns 146 shares of the company's stock worth $38,000 after purchasing an additional 55 shares during the last quarter. Montgomery Financial Services LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth $43,000. Finally, Hanseatic Management Services Inc. bought a new position in shares of Johnson & Johnson during the 3rd quarter valued at $52,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The firm's 50 day moving average is $267.43 and its 200-day moving average is $250.79. The firm has a market cap of $651.27 billion, a price-to-earnings ratio of 40.99, a price-to-earnings-growth ratio of 2.74 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business's quarterly revenue was up 5.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's payout ratio is currently 81.21%.

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Johnson & Johnson Right Now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines